Novo Nordisk AS is lowering prices of its top-selling WeGovy weight-loss drug in China, as the Danish drugmaker braces for intense competition from local rivals next year when the patent for its ...

Cuban said the high fees the FDA charges to approve generic drugs are a major barrier to manufacturing lower-priced generics in the United States, according to the report. Cuban said Cost Plus Drugs, ...

In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...

The Development: The Food and Drug Administration ("FDA") issued two draft guidance documents that would largely eliminate clinical efficacy and switching studies and instead rely on the precision of ...

AFTER AMERICA, China is the world’s largest developer of new medicines. Its companies ran nearly a third of the planet’s clinical trials last year. That is up from just 5% a decade before (see chart 1 ...

Out Of Order is a Java-based interactive game designed to test and improve the player's cognitive abilities. In this game, players are presented with a sequence of characters or numbers that are out ...

Teva Pharmaceutical Industries Limited has successfully shifted its strategy, leveraging its generics business to fund growth in specialty medicines, driving a turnaround in performance. TEVA's "Pivot ...

As lawmakers eye tougher oversight of pharmacy benefit managers, PBMs seem to be taking their own steps to rein in practices that have invited scrutiny. However, experts remain skeptical and say it ...

Fall enrollment is on. Some plans are raising premiums for Part D, which covers prescriptions, by $50 or more per month, while others are lowering them. By Mark Miller Holly Kluck found a great price ...

CEO Narasimhan says no tariff impact on guidance Top-selling heart drug Entresto sees growth stall Older drugs hit by 'generic erosion' in US market Newer drugs help offset some of the slowdown ...